Skip Navigation

JNCI Journal of the National Cancer Institute 2003 95(3):189; doi:10.1093/jnci/95.3.189
© 2003 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Garber, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Garber, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 95, No. 3, 189, February 5, 2003
© 2003 Oxford University Press

NEWS

ODAC Panel Gives Nod to Bexxar

Ken Garber

The first 10% of the full text of this article appears below.

The long journey of the experimental lymphoma treatment Bexxar (iodine 131 tositumomab) appears headed for a happy ending. In December, the U.S. Food and Drug Administration’s Oncologic Drugs Advisory Committee (ODAC) voted that Bexxar has demonstrated substantial "clinical benefit" for non-Hodgkin’s lymphoma patients who have failed either . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
J. Du, H. Wang, C. Zhong, B. Peng, M. Zhang, B. Li, S. Huo, Y. Guo, and J. Ding
Structural Basis for Recognition of CD20 by Therapeutic Antibody Rituximab
J. Biol. Chem., May 18, 2007; 282(20): 15073 - 15080.
[Abstract] [Full Text] [PDF]